Teva says hoping to launch EpiPen-like device by 2018 in U.S.

Sept 9 (Reuters) - Teva Pharmaceutical Industries Ltd

on Friday said it hopes to win U.S. approval by late

2017 or early 2018 for its version of Mylan NV's EpiPen

device to treat severe allergic reactions, a move that could

challenge the branded product's overwhelming dominance.

Read more